• Vaccine Name: LT-BCG- Ag85B /Rv3425
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Vaccine Ontology ID: VO_0004626
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Ag85B from M. tuberculosis H37Rv gene engineering:
  • Type: Recombinant vector construction
  • Description: DNA-, protein- and lentiviral vector-based vaccines that express the antigens Ag85B and Rv3425 (Xu et al., 2014).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0000359
• Preparation: DNA-, protein- and lentiviral vector-based vaccines that express the antigens Ag85B and Rv3425 (Xu et al., 2014).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Six mice per group were first immunized subcutaneously (s.c.) with 5×10^6 CFU of BCG in 100μl of PBS and subsequently boosted twice at 2-week intervals with PAR, DAR or LAR [12]. Meanwhile, the mice were boosted with the controls for these three types of vaccines, which were PNC (i.e., MPL + TDM), DNC (i.e., pVax) and LNC (i.e.,pLenti6.3). For DAR immunization, 50μg of the DAR DNA vaccine in 100μl of sterile PBS was administered to the mice intramuscularly (i.m.) in the right thigh. For LAR immunization, the mice were immunized with 5×10^6 pfu of LAR in the foot pad. For PAR immunization, the mice were immunized subcutaneously (s.c.) with 50 μg of PAR formulated with the adjuvants MPL and TDM (Xu et al., 2014).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: 2 weeks after the last vaccination, all mice were challenged intravenously via the lateral tail vein with 1.2 × 10^6 CFU of M. tuberculosis H37Rv (Xu et al., 2014).
• Efficacy: Prime-boost BCG vaccination with a lentiviral vector expressing the antigens Ag85B and Rv3425 significantly enhanced immune responses, including Th1 and CD8+ CTL responses, compared to DNA- and protein-based vaccines. However, lentivirus-vectored and DNA-based vaccines greatly improved the protective efficacy of BCG against M. tuberculosis (Xu et al., 2014).
• Information about this animal model: Mouse Model for TB research